FDA Set to Clarify the Future of Peptides in the U.S.

WHO:

Inc - Seven of the panel’s 14 members have ties to businesses or clinics involved in peptide therapies, including Tennessee State Senator Bobby Harshbarger, whose family owns a pharmacy that sells compounded medications.

Al Jazeera - Health Secretary Robert F. Kennedy Jr. has stated he has used peptides with “really good effect” and has argued that restrictions have pushed consumers into an unregulated grey market.

Inc - Seven of the panel’s 14 members have ties to businesses or clinics involved in peptide therapies, including Tennessee State Senator Bobby Harshbarger.

Inc - Diana Harshbarger, a Republican US Congressional Representative, urged Kennedy last year to loosen FDA restrictions on peptides.

Al Jazeera - The Pharmacy Compounding Advisory Committee of the US Food and Drug Administration (FDA) will include health professionals who prescribe, produce, or promote peptides.

Inc - Scott Brunner, chief executive officer of the Alliance for Pharmacy Compounding, stated that evaluating the peptides for the 503A Bulks List may prove challenging due to the lack of robust clinical trial data.

CNN - Jesse Dresser, a partner in the law firm Frier Levitt’s Life Sciences Department, explained that if the peptides are approved, patients would need to be seen by a physician and obtain a prescription from a licensed 503A compounding pharmacy.

Inc - Republican US Congressional Representative Diana Harshbarger urged Kennedy last year to loosen FDA restrictions on peptides.

Al Jazeera - The Pharmacy Compounding Advisory Committee of the US Food and Drug Administration (FDA) will meet to decide on seven peptides.

Al Jazeera - Health Secretary Robert F. Kennedy Jr. has stated he has used peptides with “really good effect.”

CNN - The FDA’s Pharmacy Compounding Advisory Committee (PCAC) will meet to discuss peptides.

CNN - US Health and Human Services Secretary Robert F. Kennedy Jr. has expressed support for peptides.

CNN - Scott Brunner is the chief executive officer of the Alliance for Pharmacy Compounding.

CNN - Jesse Dresser is a partner in the law firm Frier Levitt’s Life Sciences Department.

CNN - Edgar Asebey is a life science attorney and partner at the Frier Levitt law firm.

CNN - Dr. Castel Santana is the regional medical director at 10X Health.

CNN - Dr. Eric Topol is a research methods expert and director of Scripps Research Translational Institute.

Inc - The article discusses the FDA's potential decision regarding peptides.

WHAT:

NBC News - The FDA advisory committee voted on Thursday to add the popular peptide BPC-157 to a drug compounding list.

ABC News - The FDA's Pharmacy Compounding Advisory Committee voted to ease restrictions on BPC-157, a peptide marketed for weight loss, immunity, and skin health.

NBC News - The FDA voted by committee to ease restrictions on BPC-157, a popular peptide among influencers who market peptides as an effective treatment for weight loss, immunity, and skin health.

CNN - The FDA’s experts propose not adding the peptides to the 503A Bulks List due to a lack of evidence on effectiveness and safety.

Al Jazeera - The seven peptides under review include BPC-157, TB-500, and KPV, which are marketed for uses including ulcerative colitis, wound healing, and inflammatory conditions.

CNN - The FDA’s experts propose not adding the peptides to the 503A Bulks List due to a lack of evidence on effectiveness and safety.

Al Jazeera - The seven peptides under review include BPC-157, TB-500, and KPV, which are marketed for uses such as ulcerative colitis, wound healing, and inflammatory conditions, as well as for obesity, migraines, chronic pain, insomnia, and opioid withdrawal.

Inc - The vote could determine whether a booming out-of-pocket peptide market moves into licensed pharmacies.

CNN - The FDA's experts propose not adding the peptides to the 503A Bulks List due to a lack of evidence on effectiveness and safety.

Al Jazeera - The seven peptides under review include BPC-157, TB-500, and KPV, which are marketed for uses such as ulcerative colitis, wound healing, and inflammatory conditions.

CNN - The FDA’s experts propose not adding the peptides to the 503A Bulks List due to a lack of evidence on effectiveness and safety.

Al Jazeera - The seven peptides under review are marketed for uses including ulcerative colitis, wound healing, inflammatory conditions, obesity, migraines, chronic pain, insomnia, and opioid withdrawal.

Al Jazeera - The seven peptides under review include BPC-157, TB-500, and KPV, which are promoted for uses such as ulcerative colitis, wound healing, and inflammatory conditions.

Al Jazeera - The FDA has cited inadequate human clinical trials and concerns about the quality, stability, and consistency of the seven compounds under review.

CNN - The PCAC is scheduled to meet to review seven peptides nominated for inclusion on the FDA’s 503A Bulks List.

CNN - The FDA previously determined that certain peptides should not be compounded due to safety concerns.

CNN - The meeting will last two days, focusing on whether compounding pharmacies should dispense certain peptides.

CNN - The FDA’s experts propose not adding the peptides to the 503A Bulks List due to a lack of evidence on effectiveness and safety.

CNN - The meeting represents a pivotal moment in determining the future of peptide use in medical practice.

Inc - The vote could determine whether the peptide market moves into licensed pharmacies.

WHERE:

CNN - The meeting will take place at the FDA.

WHEN:

CNN - The PCAC meeting is scheduled for Thursday and Friday.

WHY:

Al Jazeera - Industry groups argue that the FDA should make it easier for licensed pharmacies to compound peptides to enable greater oversight of prescriptions and quality standards, as demand continues to surge for these compounds.

Al Jazeera - Industry groups argue that demand is why the FDA should make it easier for licensed pharmacies to compound peptides, thereby enabling greater oversight of prescriptions and quality standards.

CNN - Industry groups argue that the FDA should make it easier for licensed pharmacies to compound peptides to enable greater oversight of prescriptions and quality standards.

Inc - Industry groups argue that the FDA should make it easier for licensed pharmacies to compound peptides to enable greater oversight of prescriptions and quality standards.

Al Jazeera - Industry groups argue that the FDA should make it easier for licensed pharmacies to compound peptides to enable greater oversight of prescriptions and quality standards.

CNN - The meeting aims to address the growing popularity of peptides among wellness influencers and some doctors.

CNN - Supporters argue that FDA-regulated compounding pharmacies would provide a safer alternative to unregulated online sources.

CNN - Critics warn that allowing compounding could create the appearance of safety and efficacy without sufficient data.

HOW:

CNN - The committee will review seven peptides that have been nominated for inclusion on the FDA’s 503A Bulks List, which allows pharmacists to compound medications from bulk ingredients for patients with valid prescriptions.

CNN - The committee will evaluate whether the peptides meet certain criteria for inclusion on the 503A Bulks List, which allows pharmacists to compound medications from bulk ingredients for patients with valid prescriptions.

Al Jazeera - The advisory committee's recommendations are expected to help shape the FDA’s final decision, although they are not binding.

CNN - The committee will evaluate whether the peptides meet certain criteria for inclusion on the 503A Bulks List.

CNN - Compounding pharmacies would be able to prepare medications from bulk ingredients for patients with valid prescriptions if the peptides are approved.

(UPDATED July 23, 2026 20:19 UTC)

The FDA advisory committee has voted to add the popular peptide BPC-157 to a drug compounding list, which could ease restrictions on its use. This peptide is marketed for benefits like weight loss, immunity, and skin health, and industry groups are advocating for more accessible compounding to enhance oversight and quality standards amid rising demand. As the conversation around these compounds continues, the FDA's decision reflects a significant shift in how they may be regulated in the future.

(UPDATED July 23, 2026 19:21 UTC)

The FDA committee has voted to ease restrictions on BPC-157, a peptide that has gained popularity among influencers for its purported benefits in weight loss, immunity, and skin health. Seven of the committee's fourteen members have connections to businesses involved in peptide therapies, including Tennessee State Senator Bobby Harshbarger, whose family owns a pharmacy that sells compounded medications. Health Secretary Robert F. Kennedy Jr. has endorsed the use of peptides, claiming they have worked well for him, while industry groups argue that easing restrictions will help licensed pharmacies better manage the growing demand and ensure quality standards.

(UPDATED July 23, 2026 14:42 UTC)

The FDA's panel of experts has decided against adding certain peptides to the 503A Bulks List due to insufficient evidence regarding their effectiveness and safety. Among the seven peptides under review, which include BPC-157, TB-500, and KPV, they are marketed for various uses such as treating ulcerative colitis and aiding in wound healing. The committee will assess whether these peptides meet specific criteria for inclusion, while industry groups are advocating for easier access to compounding these substances to enhance oversight and quality standards.

(UPDATED July 23, 2026 13:24 UTC)

The Pharmacy Compounding Advisory Committee of the FDA will soon evaluate whether seven peptides, including BPC-157, TB-500, and KPV, should be added to the 503A Bulks List, which permits pharmacists to compound medications from bulk ingredients. Industry groups are pushing for easier access to these compounds, citing the need for better oversight and quality standards, but FDA experts are hesitant due to insufficient evidence on their effectiveness and safety. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, has noted that the lack of robust clinical trial data could make this evaluation quite challenging.

(UPDATED July 23, 2026 12:23 UTC)

The FDA's experts are recommending against adding seven peptides, including BPC-157, TB-500, and KPV, to the 503A Bulks List due to insufficient evidence regarding their effectiveness and safety. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, noted that evaluating these peptides may be challenging because of the lack of robust clinical trial data, while Jesse Dresser from Frier Levitt emphasized that patients would need a physician's prescription if the peptides are approved. Industry groups are advocating for easier access to compounding these peptides to enhance oversight and ensure quality standards in prescriptions.

(UPDATED July 23, 2026 07:49 UTC)

A panel of experts from the FDA is reviewing seven peptides that are marketed for various medical uses, including conditions like ulcerative colitis and chronic pain, but they have proposed not adding these peptides to the 503A Bulks List due to insufficient evidence regarding their effectiveness and safety. Notably, seven of the panel's 14 members have connections to businesses involved in peptide therapies, including Tennessee State Senator Bobby Harshbarger, whose family owns a pharmacy that sells compounded medications. Industry groups are advocating for the FDA to ease restrictions on compounding peptides, arguing that it would enhance oversight of prescriptions and improve quality standards.

(UPDATED July 22, 2026 22:20 UTC)

The Pharmacy Compounding Advisory Committee of the US Food and Drug Administration will meet to review seven peptides, including BPC-157, TB-500, and KPV, which are promoted for various medical uses such as ulcerative colitis and wound healing. Health Secretary Robert F. Kennedy Jr. has expressed that he has experienced “really good effect” from using these peptides, while the FDA has raised concerns about the lack of adequate human clinical trials and the quality of these compounds. Industry groups are advocating for the FDA to simplify the process for licensed pharmacies to compound these peptides, aiming to enhance oversight and ensure higher quality standards in prescriptions.

(UPDATED July 22, 2026 21:20 UTC)

The FDA’s Pharmacy Compounding Advisory Committee is set to meet for two days at the FDA to review seven peptides nominated for inclusion on the 503A Bulks List, a decision that could significantly impact the peptide market. Health and Human Services Secretary Robert F. Kennedy Jr. has expressed his support for these peptides, while critics caution that allowing compounding could mislead patients about safety and efficacy without adequate evidence. The meeting aims to address the rising popularity of peptides among wellness influencers and some medical professionals, as the committee evaluates whether these substances meet the necessary criteria for approval.